Marker Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Marker Therapeutics

22/03/2023 13:33

* Marker Therapeutics Inc  MRKR.OQ  reported a quarterly
adjusted
loss of 48 cents​​ per share for the quarter ended in December.
The lone analyst forecast for the quarter was for a loss of 100
cents per share.
    * Revenue rose 166.6% to $3.31 million from a year ago;
analysts
expected zero. 
    * Marker Therapeutics Inc's reported EPS for the quarter was
a
loss of 48 cents​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Marker Therapeutics Inc shares had fallen by 33.8% this
quarter.
    * Wall Street's median 12-month price target for Marker
Therapeutics Inc is $40.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 22 at 01:33 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.00          -0.48          Beat
 Sep. 30 2022      -1.20          -0.80          Beat
 Jun. 30 2022      -1.27          -1.10          Beat
 Mar. 31 2022      -1.33          -1.20          Beat